Ozempic vs Wegovy: What's Actually the Difference (and Why It Matters)

If you've spent any time researching GLP-1 medications, you've run into both names: Ozempic and Wegovy. They're constantly mentioned in the same breath — celebrity gossip, clinical trials, insurance fights, social media.

Here's what almost no one explains clearly: they are the same drug. Both are brand names for semaglutide, made by the same company (Novo Nordisk). The differences are in dose, FDA approval, and — most practically — how your insurance covers them.

Understanding this distinction could save you hundreds of dollars per month and a lot of frustration.

What They Have in Common

Both Ozempic and Wegovy contain semaglutide — a GLP-1 receptor agonist that works by mimicking the glucagon-like peptide-1 hormone. The mechanism is identical:

• Slows gastric emptying (you feel full longer)
• Reduces appetite signals from the brain
• Improves insulin sensitivity and blood sugar regulation
• Promotes significant weight loss when combined with lifestyle changes

Both are weekly subcutaneous injections. Both are manufactured by Novo Nordisk. Both have been through rigorous FDA clinical trials. The active molecule is the same.

What's Different

### Approved Doses

Ozempic is approved for doses up to 2.0mg weekly (0.5mg, 1.0mg, and 2.0mg pens available). The typical titration starts at 0.25mg for 4 weeks, moves to 0.5mg, and titrates up based on response.

Wegovy is approved at doses up to 2.4mg weekly — slightly higher than Ozempic's maximum. This is the dose studied in the STEP weight loss trials that produced the headline-grabbing 15% average body weight loss results.

That 0.4mg difference at the ceiling doesn't explain the large difference in real-world outcomes between patients on Ozempic vs Wegovy. What explains it is the indication — physicians prescribing Wegovy for weight loss are targeting higher doses with weight loss as the primary goal, while Ozempic is often used at lower doses for blood sugar control.

### FDA Approval Indication

Ozempic is FDA-approved for type 2 diabetes management. It was first approved in 2017. The weight loss that happens is real and significant, but the drug isn't technically approved for obesity — it's approved for glycemic control.

Wegovy is FDA-approved specifically for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. It was approved in 2021 based on the STEP trial results.

This distinction matters enormously for insurance coverage.

### Insurance Coverage

Because Ozempic is approved for diabetes and Wegovy is approved for obesity, insurance coverage follows those approvals:

• Ozempic: Typically covered for patients with type 2 diabetes. If you have T2D and insurance, Ozempic may cost $25–$100/month after copay.
• Wegovy: Weight loss coverage is inconsistent. Many commercial plans, Medicaid, and Medicare don't cover obesity drugs. When Wegovy is covered, it's often with significant prior authorization requirements.

The practical result: millions of people who want semaglutide for weight loss can't get Wegovy covered, and their doctors prescribe Ozempic "off-label" for weight loss instead. This is extremely common — off-label prescribing is legal and widespread in medicine.

### Availability and Shortages

Both medications experienced severe shortage periods in 2023–2024 as demand exploded. The shortage situation has improved but remains inconsistent by pharmacy and region.

Why Compounded Semaglutide Changes Everything

When brand-name Ozempic and Wegovy are scarce or unaffordable, FDA-outsourced compounding pharmacies can legally produce semaglutide under specific conditions. During shortage periods, this pathway opens up.

Compounded semaglutide contains the same active compound at doses prescribed by a licensed physician. The price difference is significant: $249–$349/month at Marrow vs $900–$1,350+/month for brand-name Wegovy without insurance.

The qualifications for compounded semaglutide through Marrow are similar to Wegovy's approval criteria — you need a BMI over 27 with a health goal, assessed during a physician consultation.

What This Means For You

If you're trying to decide between Ozempic and Wegovy, the real decision tree is:

Do you have type 2 diabetes? → Talk to your primary care doc about Ozempic. Insurance likely covers it.

Do you want weight loss and have insurance that covers Wegovy? → Check your formulary. Prior auth will probably be required. Could work out well financially if approved.

Neither of the above? → Compounded semaglutide is the practical path for most patients. Same active compound, physician oversight included, fraction of the brand-name cost.

The drug is the drug. The brand on the label and the approval indication determine the price and access path — not the efficacy.

Starting Semaglutide Through Marrow

At Marrow, the intake process starts with a physician consultation that reviews your health history, goals, and any contraindications. If you qualify, compounded semaglutide ships in 5–7 business days at $249/month — physician oversight included.

There's no insurance required, no prior authorization, and no pharmacy shortage to navigate. If you've been stuck trying to access Ozempic or Wegovy through traditional channels, this is the direct path.

[Start your intake](/start) to see if you qualify. Most patients receive their first shipment within a week of approval.